dc.contributor.author | Edmunds, Kim | |
dc.contributor.author | Scuffham, Paul | |
dc.contributor.author | Reeves, Penny | |
dc.contributor.author | Galvão, Daniel A | |
dc.contributor.author | Taaffe, Dennis R | |
dc.contributor.author | Newton, Robert U | |
dc.contributor.author | Spry, Nigel | |
dc.contributor.author | Joseph, David | |
dc.contributor.author | Tuffaha, Haitham | |
dc.date.accessioned | 2021-07-01T03:41:07Z | |
dc.date.available | 2021-07-01T03:41:07Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 0961-5423 | |
dc.identifier.doi | 10.1111/ecc.13479 | |
dc.identifier.uri | http://hdl.handle.net/10072/405508 | |
dc.description.abstract | Prostate cancer (PCa) patients with bone metastases tend to have significant functional impairment from long-term androgen deprivation therapy (ADT), exacerbated by subsequent treatments such as second-line hormone therapies (abiraterone and enzalutamide), first- and second-line chemotherapy or immunotherapies (Hart et al., 2017). They are at significant risk of falls, fractures and consequent hospitalisation. There is a growing body of evidence to support the effectiveness of exercise in addressing the adverse effects of advanced PCa treatment (Hayes et al., 2019). Despite recommendations for men with bone metastases to participate in supervised exercise, there is often a reticence on the part of clinicians and/or patients due to concerns of fragility fracture or other adverse effects (Hart et al., 2017). These men with significant treatment toxicity and a high disease burden are an important patient group for whom exercise has been demonstrated to improve quality of life (QoL) (Galvão et al., 2018). To inform policy and improve accessibility of exercise for advanced PCa patients, it is important to determine whether such interventions represent value for money. | |
dc.description.peerreviewed | Yes | |
dc.language | eng | |
dc.publisher | Wiley | |
dc.relation.ispartofjournal | European Journal of Cancer Care | |
dc.subject.fieldofresearch | Nursing | |
dc.subject.fieldofresearch | Oncology and carcinogenesis | |
dc.subject.fieldofresearch | Health services and systems | |
dc.subject.fieldofresearch | Public health | |
dc.subject.fieldofresearchcode | 4205 | |
dc.subject.fieldofresearchcode | 3211 | |
dc.subject.fieldofresearchcode | 4203 | |
dc.subject.fieldofresearchcode | 4206 | |
dc.subject.keywords | cost-effectiveness analysis | |
dc.subject.keywords | economic evaluation | |
dc.subject.keywords | exercise medicine | |
dc.subject.keywords | metastatic prostate cancer | |
dc.subject.keywords | value of information analysis | |
dc.title | Demonstrating the value of early economic evaluation alongside clinical trials: Exercise medicine for men with metastatic prostate cancer | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dcterms.bibliographicCitation | Edmunds, K; Scuffham, P; Reeves, P; Galvão, DA; Taaffe, DR; Newton, RU; Spry, N; Joseph, D; Tuffaha, H, Demonstrating the value of early economic evaluation alongside clinical trials: Exercise medicine for men with metastatic prostate cancer, European Journal of Cancer Care, 2021 | |
dcterms.dateAccepted | 2021-03-23 | |
dc.date.updated | 2021-06-28T23:30:37Z | |
dc.description.version | Accepted Manuscript (AM) | |
gro.description.notepublic | This publication has been entered as an advanced online version in Griffith Research Online. | |
gro.rights.copyright | © 2021 John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Demonstrating the value of early economic evaluation alongside clinical trials: Exercise medicine for men with metastatic prostate cancer, European Journal of Cancer Care, 2021, which has been published in final form at https://doi.org/10.1111/ecc.13479. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html) | |
gro.hasfulltext | Full Text | |
gro.griffith.author | Scuffham, Paul A. | |